JP Morgan Chase’s Ascendis Pharma A/S ASND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.64M Hold
35,000
﹤0.01% 2932
2025
Q4
$7.46M Sell
35,000
-40,100
-53% -$8.28M ﹤0.01% 2962
2025
Q3
$14.9M Buy
+75,100
New +$14M ﹤0.01% 2345
2023
Q4
Sell
-25,000
Closed -$2.34M 7504
2023
Q3
$2.34M Sell
25,000
-75,000
-75% -$7.02M ﹤0.01% 3440
2023
Q2
$8.93M Buy
100,000
+25,000
+33% +$2.18M ﹤0.01% 2383
2023
Q1
$8.04M Buy
+75,000
New +$8.58M ﹤0.01% 2469
2022
Q2
Sell
-3,000
Closed -$352K 6445
2022
Q1
$352K Buy
+3,000
New +$347K ﹤0.01% 4898
2021
Q1
Sell
-27,000
Closed -$4.5M 6051
2020
Q4
$4.5M Buy
+27,000
New +$4.46M ﹤0.01% 2898
2020
Q1
Sell
-36,000
Closed -$5.01M 5278
2019
Q4
$5.01M Buy
+36,000
New +$4M ﹤0.01% 2674

Other funds holding ASND

JP Morgan Chase's ASND Position: Q1 2026 in Review

JP Morgan Chase increased its Ascendis Pharma A/S (ASND) stake by 6.3% in Q1 2026, buying an estimated $7.22M and bringing the position to 539,434 shares worth $118M. The position accounts for 0.01% of the portfolio, ranked #912.

JP Morgan Chase first reported a position in ASND in Q3 2017 and has held it in 32 quarters since. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • JP Morgan Chase held 539,434 shares of Ascendis Pharma A/S worth $118M as of Q1 2026.
  • JP Morgan Chase bought 32,194 Ascendis Pharma A/S shares in Q1 2026, an estimated $7.22M.
  • Ascendis Pharma A/S made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #912 holding.
  • JP Morgan Chase first reported a position in Ascendis Pharma A/S in Q3 2017 and has held it in 32 quarters since.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.